Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence

Hepatology

Volumn 57, Issue 4, 2013, Pages 1665-1667

  Bosch, Jaime ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; ISOSORBIDE MONONITRATE; NADOLOL;

ADVERSE OUTCOME; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; FOLLOW UP; HUMAN; NOTE; PRIORITY JOURNAL; RECURRENT DISEASE; STOMACH VARICES BLEEDING; SURVIVAL; UNSPECIFIED SIDE EFFECT;

EID: 84876155283     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26279     Document Type: Note

References (6)

1. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. HEPATOLOGY 2010; 51: 2214-2218.
2. Bañares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. HEPATOLOGY 2002; 36: 1367-1373.
3. Tripathi D, Hayes PC. The role of carvedilol in the managemet of portal hypertension. Eur J Gastroenterol Hepatol 2010; 22: 905-911.
4. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-832.
5. Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the preventionof the first variceal bleed. HEPATOLOGY 2009; 50: 825-833.
6. Lo GH, Chen WC, Wang HM, Yu HC. A randomized, controlled trial of carvedilol vs. nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol 2012; 27: 1681-1687.